Sign In
Buy MYNZ
$0.700
+0 (+0%)
At Close: Jun 03, 2026
Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test
08:01am, Wednesday, 25'th Jun 2025
BERKELEY, Calif. and MAINZ, Germany, June 25, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project
09:01am, Tuesday, 10'th Jun 2025
BERKELEY, Calif. and MAINZ, Germany, June 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants
08:01pm, Monday, 19'th May 2025
BERKELEY, Calif. and MAINZ, Germany, May 19, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study
08:01am, Friday, 16'th May 2025
Company intends to provide an interim read out by the end of summer 2025 Top-line results anticipated in Q4 2025; study on track to support U.S. pivotal trial initiation in 2026 BERKELEY, Calif. and M
Mainz Biomed Enters into Technology Partnership with EDX Medical Group
08:01am, Tuesday, 29'th Apr 2025
BERKELEY, Calif. and MAINZ, Germany, April 29, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval
08:01am, Monday, 28'th Apr 2025
BERKELEY, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study
09:01am, Thursday, 27'th Mar 2025
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed's Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples Study is on Track to Report To
Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer
08:01am, Thursday, 13'th Mar 2025
Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood Samples Mainz Biomed Enters into Exclusive Licensing Agreement
Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention
08:01am, Monday, 03'rd Mar 2025
BERKELEY, Calif. and MAINZ, Germany, March 03, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Expands into Switzerland with labor team w
08:01am, Thursday, 20'th Feb 2025
BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month
08:01am, Tuesday, 11'th Feb 2025
BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
08:01am, Monday, 27'th Jan 2025
BERKELEY, Calif. and MAINZ, Germany, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in
eAArly DETECT 2 feasibility study designed to validate earlier results on advanced adenomas over a large population of average risk patients Multi-center study expected to complete enrollment in the s
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
08:01am, Thursday, 19'th Dec 2024
BERKELEY, Calif. and MAINZ, Germany, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
05:00pm, Monday, 16'th Dec 2024
BERKELEY, Calif. and MAINZ, Germany, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V.
